Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Identifieur interne : 000001 ( PubMed/Corpus ); précédent : 000000; suivant : 000002Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Auteurs : Miljana Nenkov ; Yunxia Ma ; Daniela Haase ; Zhongwei Zhou ; Yong Li ; Iver Petersen ; Guanghua Lu ; Yuan ChenSource :
- Oncology reports [ 1791-2431 ] ; 2020.
Abstract
Mutations of p53 occur in approximately 50% of advanced non‑small cell lung cancer (NSCLC) cases, leading to loss of tumor suppressive function and/or gain of p53 oncogenic activity. Reactivation of mutant p53 and consequently induction of apoptosis in cancer cells is the goal of p53‑targeted therapy. Recently, several p53 mutant reactivating compounds were discovered including SCH 529074. However, the role of SCH 529074 in NSCLC has not been fully explored. In the present study, the effects of this compound on cell survival, cell cycle progression, induction of apoptosis and modulation of cell signaling in p53 mutant NSCLC cells (H1975, H322 and H157) and p53 wild‑type NSCLC cells (A549), was investigated. Cell‑based functional assays, real‑time RT‑qPCR and western blot assays were used. HCT116 [p53 wild‑type (WT)] and HCT116 p53‑/‑ (p53 null) were used as control cells. The results demonstrated that SCH 529074 treatment caused significant reduction in cell viability and colony formation activity in p53 mutant, p53 WT and p53‑deficient cells. The treatment of NSCLC cells with SCH 529074 resulted in a dose‑dependent induction of apoptosis and G0/G1 cell cycle arrest, which was associated with the activation of caspases (3 and 7), p53‑independent upregulation of p21 and PUMA as well as increased LC3II, a biomarker of autophagy. The combination treatment with the autophagy inhibitor chloroquine (CQ) and SCH 529074 led to decreased cell viability, colony formation and increased induction of apoptosis. The data indicated that SCH 529074 may exert its growth inhibitory function in a p53‑independent manner in NSCLC cells.
DOI: 10.3892/or.2020.7546
PubMed: 32186773
Links to Exploration step
pubmed:32186773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.</title>
<author><name sortKey="Nenkov, Miljana" sort="Nenkov, Miljana" uniqKey="Nenkov M" first="Miljana" last="Nenkov">Miljana Nenkov</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Yunxia" sort="Ma, Yunxia" uniqKey="Ma Y" first="Yunxia" last="Ma">Yunxia Ma</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Haase, Daniela" sort="Haase, Daniela" uniqKey="Haase D" first="Daniela" last="Haase">Daniela Haase</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhou, Zhongwei" sort="Zhou, Zhongwei" uniqKey="Zhou Z" first="Zhongwei" last="Zhou">Zhongwei Zhou</name>
<affiliation><nlm:affiliation>Leibniz Institute on Ageing‑Fritz Lipmann Institute (FLI), D‑07745 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Yong" sort="Li, Yong" uniqKey="Li Y" first="Yong" last="Li">Yong Li</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Petersen, Iver" sort="Petersen, Iver" uniqKey="Petersen I" first="Iver" last="Petersen">Iver Petersen</name>
<affiliation><nlm:affiliation>Institute of Pathology, SRH Wald‑Klinikum, D‑07548 Gera, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Guanghua" sort="Lu, Guanghua" uniqKey="Lu G" first="Guanghua" last="Lu">Guanghua Lu</name>
<affiliation><nlm:affiliation>School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Yuan" sort="Chen, Yuan" uniqKey="Chen Y" first="Yuan" last="Chen">Yuan Chen</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32186773</idno>
<idno type="pmid">32186773</idno>
<idno type="doi">10.3892/or.2020.7546</idno>
<idno type="wicri:Area/PubMed/Corpus">000001</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000001</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.</title>
<author><name sortKey="Nenkov, Miljana" sort="Nenkov, Miljana" uniqKey="Nenkov M" first="Miljana" last="Nenkov">Miljana Nenkov</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Yunxia" sort="Ma, Yunxia" uniqKey="Ma Y" first="Yunxia" last="Ma">Yunxia Ma</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Haase, Daniela" sort="Haase, Daniela" uniqKey="Haase D" first="Daniela" last="Haase">Daniela Haase</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhou, Zhongwei" sort="Zhou, Zhongwei" uniqKey="Zhou Z" first="Zhongwei" last="Zhou">Zhongwei Zhou</name>
<affiliation><nlm:affiliation>Leibniz Institute on Ageing‑Fritz Lipmann Institute (FLI), D‑07745 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Li, Yong" sort="Li, Yong" uniqKey="Li Y" first="Yong" last="Li">Yong Li</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Petersen, Iver" sort="Petersen, Iver" uniqKey="Petersen I" first="Iver" last="Petersen">Iver Petersen</name>
<affiliation><nlm:affiliation>Institute of Pathology, SRH Wald‑Klinikum, D‑07548 Gera, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lu, Guanghua" sort="Lu, Guanghua" uniqKey="Lu G" first="Guanghua" last="Lu">Guanghua Lu</name>
<affiliation><nlm:affiliation>School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Yuan" sort="Chen, Yuan" uniqKey="Chen Y" first="Yuan" last="Chen">Yuan Chen</name>
<affiliation><nlm:affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Oncology reports</title>
<idno type="eISSN">1791-2431</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mutations of p53 occur in approximately 50% of advanced non‑small cell lung cancer (NSCLC) cases, leading to loss of tumor suppressive function and/or gain of p53 oncogenic activity. Reactivation of mutant p53 and consequently induction of apoptosis in cancer cells is the goal of p53‑targeted therapy. Recently, several p53 mutant reactivating compounds were discovered including SCH 529074. However, the role of SCH 529074 in NSCLC has not been fully explored. In the present study, the effects of this compound on cell survival, cell cycle progression, induction of apoptosis and modulation of cell signaling in p53 mutant NSCLC cells (H1975, H322 and H157) and p53 wild‑type NSCLC cells (A549), was investigated. Cell‑based functional assays, real‑time RT‑qPCR and western blot assays were used. HCT116 [p53 wild‑type (WT)] and HCT116 p53‑/‑ (p53 null) were used as control cells. The results demonstrated that SCH 529074 treatment caused significant reduction in cell viability and colony formation activity in p53 mutant, p53 WT and p53‑deficient cells. The treatment of NSCLC cells with SCH 529074 resulted in a dose‑dependent induction of apoptosis and G0/G1 cell cycle arrest, which was associated with the activation of caspases (3 and 7), p53‑independent upregulation of p21 and PUMA as well as increased LC3II, a biomarker of autophagy. The combination treatment with the autophagy inhibitor chloroquine (CQ) and SCH 529074 led to decreased cell viability, colony formation and increased induction of apoptosis. The data indicated that SCH 529074 may exert its growth inhibitory function in a p53‑independent manner in NSCLC cells.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32186773</PMID>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-2431</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Oncology reports</Title>
<ISOAbbreviation>Oncol. Rep.</ISOAbbreviation>
</Journal>
<ArticleTitle>Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.3892/or.2020.7546</ELocationID>
<Abstract><AbstractText>Mutations of p53 occur in approximately 50% of advanced non‑small cell lung cancer (NSCLC) cases, leading to loss of tumor suppressive function and/or gain of p53 oncogenic activity. Reactivation of mutant p53 and consequently induction of apoptosis in cancer cells is the goal of p53‑targeted therapy. Recently, several p53 mutant reactivating compounds were discovered including SCH 529074. However, the role of SCH 529074 in NSCLC has not been fully explored. In the present study, the effects of this compound on cell survival, cell cycle progression, induction of apoptosis and modulation of cell signaling in p53 mutant NSCLC cells (H1975, H322 and H157) and p53 wild‑type NSCLC cells (A549), was investigated. Cell‑based functional assays, real‑time RT‑qPCR and western blot assays were used. HCT116 [p53 wild‑type (WT)] and HCT116 p53‑/‑ (p53 null) were used as control cells. The results demonstrated that SCH 529074 treatment caused significant reduction in cell viability and colony formation activity in p53 mutant, p53 WT and p53‑deficient cells. The treatment of NSCLC cells with SCH 529074 resulted in a dose‑dependent induction of apoptosis and G0/G1 cell cycle arrest, which was associated with the activation of caspases (3 and 7), p53‑independent upregulation of p21 and PUMA as well as increased LC3II, a biomarker of autophagy. The combination treatment with the autophagy inhibitor chloroquine (CQ) and SCH 529074 led to decreased cell viability, colony formation and increased induction of apoptosis. The data indicated that SCH 529074 may exert its growth inhibitory function in a p53‑independent manner in NSCLC cells.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nenkov</LastName>
<ForeName>Miljana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Yunxia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haase</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Zhongwei</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Leibniz Institute on Ageing‑Fritz Lipmann Institute (FLI), D‑07745 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Petersen</LastName>
<ForeName>Iver</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Institute of Pathology, SRH Wald‑Klinikum, D‑07548 Gera, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Guanghua</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Yuan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Section Pathology of The Institute of Forensic Medicine, University Hospital Jena, Friedrich Schiller University, D‑07747 Jena, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>03</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Greece</Country>
<MedlineTA>Oncol Rep</MedlineTA>
<NlmUniqueID>9422756</NlmUniqueID>
<ISSNLinking>1021-335X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>01</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>12</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32186773</ArticleId>
<ArticleId IdType="doi">10.3892/or.2020.7546</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000001 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000001 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:32186773 |texte= Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32186773" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |